UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Comprehensive pediatric CAR T guidelines developed by MD Anderson and PALISI
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL
Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is associated with alterations in brain activation during attention and executive-function tasks, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit ov...
Source: Amgen News Release - June 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novel CD22 CAR-T Works After CD19 Product Failed Novel CD22 CAR-T Works After CD19 Product Failed
A novel CAR T-cell therapy directed against CD22 worked in children with acute lymphoblastic leukemia who had previously progressed after receiving CD19-directed CAR T-cell therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

' Too Clean' Could Be a Trigger for Childhood Acute Leukemia'Too Clean' Could Be a Trigger for Childhood Acute Leukemia
A lack of microbial exposure among children in industrialized countries may contribute to the development of childhood B-cell acute lymphoblastic leukemia, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Early exposure to microbes may protect against childhood leukemia
A new analysis suggests that childhood acute lymphoblastic leukemia likely results from genetic predisposition and limited early exposure to germs. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

New 'unified theory' of childhood leukemia raises possibility of preventing the disease
Kids who develop acute lymphoblastic leukemia may be the victims of a triple-whammy stroke of bad luck, according to a provocative new theory from a respected British cancer researcher.If the explanation turns out to be correct, it would be good news for the most common type of childhood cancer:... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - May 23, 2018 Category: Science Authors: Melissa Healy Source Type: news

' Best Survival Data Ever' in Young T-Cell Leukemia Patients'Best Survival Data Ever' in Young T-Cell Leukemia Patients
Moving nelarabine to the front line and combining it with methotrexate improved 4-year disease-free survival in young patients with T-cell acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ultra-Clean Homes Can Raise Childhood Cancer Risk, Study Finds
LONDON (CBS Local) – A groundbreaking study into what triggers cancer has found that children who are “too hygienic” and are kept away from other kids were at greater risk for developing leukemia. The Details: A cancer study has found that children living in ultra-clean environments have higher rates of leukemia Professor Mel Greaves says children need to have their immune system “primed” by exposure to various germs Greaves found that children with siblings or who were breastfed had lower rates of the disease Professor Mel Greaves from the Institute of Cancer Research (ICR) in London h...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News childhood cancer Children Chris Melore Germs Leukemia Local TV talkers Source Type: news

Leading UK scientist reveals likely cause of childhood leukaemia
(Institute of Cancer Research) A major new analysis reveals the likely cause of most cases of childhood leukaemia, following more than a century of controversy about its origins.Professor Mel Greaves assessed the most comprehensive body of evidence ever collected on acute lymphoblastic leukaemia (ALL). He concludes the disease is caused through a two-step process of genetic mutation and exposure to infection that means it may be preventable with treatments to stimulate or 'prime' the immune system in infancy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 21, 2018 Category: Biology Source Type: news

New regimens improve survival for children and young adults with T-cell cancers
(American Society of Clinical Oncology) In a federally funded, randomized phase III clinical trial performed by the Children's Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84 percent were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

Crucial Mutations Found in T-Cell ALL
T-ALL may be treatable by targeting signaling pathways affected by STIL-TAL1 fusion, according to a team from The Institute of Cancer Research, London, UK. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Lymphoblastic Leukemia News Source Type: news

Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Cancer cell cycle inhibitor is Lin BioScience's second candidate to receive Orphan Drug Designation SAN DIEGO, April 24, 2018 -- (Healthcare Sales & Marketing Network) -- Lin BioScience, a drug development company targeting unmet clinical needs in onco... Biopharmaceuticals, Oncology, FDA Lin BioScience, LBS-007, acute lymphoblastic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 24, 2018 Category: Pharmaceuticals Source Type: news

Targeting JAK3 and HOXA9 to Combat T-Cell ALL?
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Lymphoblastic Leukemia Hematologic Malignancies News Source Type: news

Inspirational cancer victim DIES months after having an abortion
Charlotte Smith, from North Yorkshire, was diagnosed with acute lymphoblastic leukaemia when she was 11 weeks pregnant. Doctors warned carrying a child posed a danger to her life. (Source: the Mail online | Health)
Source: the Mail online | Health - April 10, 2018 Category: Consumer Health News Source Type: news

CAR T-Cell Therapy in ALL: Formidible Challenges Remain
At the NCCN Annual Conference, Dr. Bijal Shah of Tampa ’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2018 Category: Cancer & Oncology Authors: Roxanne Nelson Tags: Acute Lymphoblastic Leukemia Conferences/NCCN News Source Type: news

FDA Expands Blinatumomab Approval for ALL to Include MRD
The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD. (Source: CancerNetwork)
Source: CancerNetwork - April 3, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Acute Lymphoblastic Leukemia Hematologic Malignancies News Source Type: news

Blincyto OK'd for MRD-Positive Acute Lymphoblastic Leukemia
(MedPage Today) -- Residual disease undetectable in 70 of 86 patients treated (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 29, 2018 Category: American Health Source Type: news

FDA Approves BLINCYTO ® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease Detection of Remaining Cancer Cells After Complete Remission is the Strongest Prognostic Factor for Relapse in Patients With Acute Lymphoblastic Leukemia Accelerated Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., March 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (bl...
Source: Amgen News Release - March 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Blincyto Approval Expanded for Specific Leukemia
THURSDAY, March 29, 2018 -- The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who still have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 29, 2018 Category: General Medicine Source Type: news

FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
March 29, 2018 -- The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 29, 2018 Category: Drugs & Pharmacology Source Type: news

Two genes cooperate to trigger leukemia development
(VIB (the Flanders Institute for Biotechnology)) An international group of researchers led by Professor Jan Cools of the VIB-KU Leuven Center for Cancer Biology have made a breakthrough in understanding the development of acute lymphoblastic leukemia, an aggressive cancer of the blood. While scientists were already familiar with many cancer-causing genes and their separate functions, the VIB team has now illustrated how two of these cancer genes work together to trigger leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 20, 2018 Category: Cancer & Oncology Source Type: news

FDA Panel Gives Nod to New Blincyto Use in ALL FDA Panel Gives Nod to New Blincyto Use in ALL
Blinatumomab would become the first treatment for which minimal residual disease positivity would be a selection criterion and MRD negativity an endpoint for acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO ® (blinatumomab)
First-Ever Application to be Submitted for an MRD Positive Indication THOUSAND OAKS, Calif., Feb. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL) at a meeting on March 7, 2018. MRD refers to the presence of a small amount of detectible cancer cells that remain in the patien...
Source: Amgen News Release - February 14, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

How Cancer Immunotherapy Is Getting Even Better
Last year, the Food and Drug Administration approved two new immunotherapies to treat certain leukemias and lymphomas. Now, in a study published in the New England Journal of Medicine, researchers detail who is most likely to benefit from the treatments, called CAR T cell therapy. CAR T cell therapy trains the body’s immune system to target and destroy cancer cells in the blood; scientists take people’s own immune cells (T cells) and genetically engineer them to seek out and destroy cancer cells. The immune system can then attack cancer cells in the same way it does bacteria and viruses, and the therapy can lea...
Source: TIME: Health - February 2, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer cancer cells cancer immunotherapy CAR T car t cell therapy car t gene therapy car t therapy cure for cancer healthytime leukemia leukemia treatments Source Type: news

New CAR T Cell for Adult ALL,'Game Changer' in Pediatric ALL New CAR T Cell for Adult ALL,'Game Changer' in Pediatric ALL
A new CAR T cell has shown efficacy in adults with acute lymphoblastic leukemia (ALL), as the first of these products is hailed as a'game changer'in pediatric ALL.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Poorer survival rates for adults with acute lymphoblastic leukaemia in deprived areas
(University of Sheffield) Adults with acute lymphoblastic leukaemia living in deprived areas of England have poorer survival rates, a new study has found. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 1, 2018 Category: International Medicine & Public Health Source Type: news

Simmons Cancer Center researchers part of historic CAR-T breakthrough
(UT Southwestern Medical Center) A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia in children and young adults. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2018 Category: Cancer & Oncology Source Type: news

T cell therapy shows persistent benefits in young leukemia patients
(Children's Hospital of Philadelphia) Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia (ALL), reveal that children and young adults continued to show high rates of durable, complete remission of their disease. Most side effects were short-lived and reversible. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 31, 2018 Category: Cancer & Oncology Source Type: news

New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
Positive Overall Survival Data From Phase 3 ASPIRE Trial on KYPROLIS® (Carfilzomib) in Relapsed Multiple Myeloma to be Highlighted in Oral Presentation Results From Several Abstracts Highlight the Potential of Amgen's Bispecific T Cell Engager (BiTE®) Platform as an Innovative Approach to Treating Blood Cancers FDA Grants Priority Review for BLINCYTO (Blinatumomab) Supplemental Biologics License Application in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33...
Source: Amgen News Release - December 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

The Leukemia & Lymphoma Society awards grant to Savoldo for immunotherapy research
(UNC Lineberger Comprehensive Cancer Center) A grant from The Leukemia& Lymphoma Society will help fund clinical research led by UNC Lineberger's Barbara Savoldo, MD, PhD, into an investigational chimeric antigen receptor (CAR) T-cell treatment for acute lymphoblastic leukemia that would include a built-in 'safety switch.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 21, 2017 Category: Cancer & Oncology Source Type: news

Seattle Children's opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins
(Seattle Children's) Seattle Children's has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the US for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2017 Category: International Medicine & Public Health Source Type: news

CHLA is awarded more than $1M from St. Baldrick's Foundation to fund cancer research
(Children's Hospital Los Angeles) Three physician-researchers with the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles (CHLA) have been awarded more than $1 million in grants from the St. Baldrick's Foundation, the largest private funder of childhood cancer research. The funding will be used to support research efforts spanning both neuroblastoma and acute lymphoblastic leukemia -- two of the most aggressive childhood cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2017 Category: Cancer & Oncology Source Type: news

CHLA is awarded more than $1 million from St. Baldrick's Foundation to fund cancer research
(Children's Hospital Los Angeles) Three physician-researchers with the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles (CHLA) have been awarded more than $1 million in grants from the St. Baldrick's Foundation, the largest private funder of childhood cancer research. The funding will be used to support research efforts spanning both neuroblastoma and acute lymphoblastic leukemia -- two of the most aggressive childhood cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2017 Category: Cancer & Oncology Source Type: news

MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia
Activating mutations in the gene encoding the cell-cell contact signaling protein Notch1 are common in human T cell acute lymphoblastic leukemias (T-ALLs). However, expressing Notch1 mutant alleles in mice fails to efficiently induce the development of leukemia. We performed a gain-of-function screen to identify proteins that enhanced signaling by leukemia-associated Notch1 mutants. The transcription factors MAFB and ETS2 emerged as candidates that individually enhanced Notch1 signaling, and when coexpressed, they synergistically increased signaling to an extent similar to that induced by core components of the Notch trans...
Source: Signal Transduction Knowledge Environment - November 14, 2017 Category: Science Authors: Pajcini, K. V., Xu, L., Shao, L., Petrovic, J., Palasiewicz, K., Ohtani, Y., Bailis, W., Lee, C., Wertheim, G. B., Mani, R., Musuthamy, N., Li, Y., Meijerink, J. P. P., Blacklow, S. C., Faryabi, R. B., Cherry, S., Pear, W. S. Tags: STKE Research Articles Source Type: news

Childhood Acute Lymphoblastic Leukemia (ALL)
Title: Childhood Acute Lymphoblastic Leukemia (ALL)Category: Diseases and ConditionsCreated: 10/28/2009 12:00:00 AMLast Editorial Review: 10/11/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 11, 2017 Category: Cancer & Oncology Source Type: news

BU researcher receives grant to better understand lymphoblastic leukemia
(Boston University School of Medicine) Hui Feng, M.D., Ph.D., assistant professor of pharmacology and medicine at Boston University School of Medicine (BUSM), is the recipient of a four-year, $792,000 grant from the American Cancer Society to study why T-cell acute lymphoblastic leukemia (T-ALL) is so aggressive and resistant to treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2017 Category: Cancer & Oncology Source Type: news

Rates and Trends of Pediatric Acute Lymphoblastic Leukemia Rates and Trends of Pediatric Acute Lymphoblastic Leukemia
This report examines the latest demographic and geographic trends in ALL incidence among children and adolescents in the U.S.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

How to manage family life when your child has cancer
Valerie, with husband Doron, son Evan and daughter Ruby When our daughter, Ruby, was diagnosed with acute lymphoblastic leukemia (ALL) at one and a half years old, my husband and I were immediately transformed from working parents with two young children, to parental caregivers for a child with cancer. Between hospital stays, medications and appointments, there was so much to keep track of. It can be overwhelming at times, but there are ways to manage life after your child is diagnosed with cancer. Settle into to this new normal. It can be easy to stay in crisis mode when something like a cancer diagnosis interrupts y...
Source: Thrive, Children's Hospital Boston - September 20, 2017 Category: Pediatrics Authors: Valerie Graf Tags: Diseases & Conditions Parenting Cancer Dana-Farber/Boston Children's Cancer and Blood Disorders Center Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukaemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukaemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukaemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10 percent of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news

Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 14, 2017 Category: American Health Source Type: news

Adult Acute Lymphoblastic Leukemia (ALL)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 14, 2017 Category: General Medicine Source Type: news

Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment
Canadian drug discovery and development company Pascal Biosciences has executed an exclusive, worldwide licence option agreement with STC.UNM (STC) to purchase a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukaemia (BCP- … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia
Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news